Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma
Conclusion: Biweekly administration of ramucirumab plus paclitaxel did not compromise efficacy. Delays, adjustments, or doses held were similar to the RAINBOW trial, with 31% requiring a dose or schedule modification.Oncology
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Databases & Libraries | Gastric (Stomach) Cancer | Gastroenterology